Is Fractyl Health, Inc. Common Stock (GUTS) overvalued? · $74.9M cap
Fractyl Health, Inc. Common Stock (GUTS) is a biotechnology company listed on US.
This page asks whether Fractyl Health, Inc. Common Stock (GUTS) looks expensive on cached numbers — not a short thesis.
No cached income statement for GUTS, so there is no earnings base to call rich or cheap.
GUTS currently screens at market cap $74.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GUTS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GUTS stock page for the full model, not this heading.
Not investment advice.